SymBio Pharmaceuticals Limited
SYMQY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $8,681 | $9,561 | $26,363 | $10,803 |
| - Cash | $3,964 | $6,517 | $6,283 | $3,860 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4,717 | $3,044 | $20,081 | $6,943 |
| Revenue | $2,453 | $5,590 | $10,008 | $8,253 |
| % Growth | -56.1% | -44.1% | 21.3% | – |
| Gross Profit | $1,873 | $4,411 | $7,600 | $5,800 |
| % Margin | 76.4% | 78.9% | 75.9% | 70.3% |
| EBITDA | -$3,779 | -$716 | $2,062 | $1,110 |
| % Margin | -154.1% | -12.8% | 20.6% | 13.4% |
| Net Income | -$3,833 | -$1,963 | $1,179 | $2,032 |
| % Margin | -156.3% | -35.1% | 11.8% | 24.6% |
| EPS Diluted | -84.06 | -49.19 | 29.77 | 52.32 |
| % Growth | -70.9% | -265.2% | -43.1% | – |
| Operating Cash Flow | -$3,417 | -$195 | $1,614 | $140 |
| Capital Expenditures | -$47 | -$233 | -$48 | -$64 |
| Free Cash Flow | -$3,463 | -$427 | $1,567 | $76 |